Novartis plans worldwide filings of panobinostat
This article was originally published in Scrip
Executive Summary
Novartis plans to submit worldwide regulatory applications for panobinostat (LBH589) after reporting positive final data from a pivotal Phase II trial of the oral pan-deacetylase (DAC) inhibitor to treat relapsed or refractory Hodgkin's lymphoma.